COMP <GO>
INSP vs MRK // REVENUE GROWTH (YOY)
Inspire Medical Systems Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: INSP 6
— MRK 6
▲ REVENUE GROWTH (YOY) LEADER: INSP
LAST: $68.10 (-4.33%) • MKT CAP: $2.06B
revenue-growth
13.60%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSP VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSP | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.40% | 74.80% | +10.60 | INSP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 20.70% | -14.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.3x | 15.3x | +8.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.81% | 3.42% | +0.39 | INSP | /fcf-yield <GO> |
| Operating Margin | 5.60% | 34.30% | -28.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 15.90% | 28.10% | -12.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 13.60% | 1.30% | +12.30 | INSP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.40 | 5.19 | +6.21 | INSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.5 | 51.7 | +1.80 | INSP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 18.4x | -6.50 | INSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.06B | $361.02B | -$358.96B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSP REV | MRK REV | INSP GROSS % | MRK GROSS % | INSP FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $912.0M | $65.01B | 85.4% | 74.8% | $78.5M | $12.36B |
| FY 2024 | $802.8M | $64.17B | 84.7% | 76.3% | $91.1M | $18.10B |
| FY 2023 | $624.8M | $60.12B | — | — | $24.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSP // BETA —
MRK // BETA 0.92